Moreover, MLL frequently hosts international research cooperation directly: For instance through exchange programs, our test procedures and data repositories, but also by allowing guest researchers to shadow the work of our facility and by sitting on national and international work groups.

We also support research institutions around the world to produce new insight in the field of leukemia diagnostics and emergence, as well as in the rollout of new procedures and applications for routine diagnostics in the facilities themselves.

Publications

Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

Bach E, Krahl R, Lange T, Schüler F, Al-Ali H, Büchner T, Haferlach T, Dölken G, Niederwieser D, Cross M. Delayed Processing of Bone Marrow Samples Reveals a Prognostic Pattern of NME mRNA Expression in Cytogenetically Normal AML. Leuk Lymphoma. 2012;53(8):1561-1568.

Bacher U, Haferlach C, Schnittger S, Kern W, Ott MM, Haferlach T. Diagnostics of acute leukemias: Interaction of phenotypic and genetic methods. Pathologe. 2012;33(6):528-538.

Bacher U, Haferlach T. The benefit of population-based studies for older patients with acute myeloid leukemia. Haematologica. 2012;97(12):1781-1782.

Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T. Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res. 2012;36(7):826-831.

Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML supporting the WHO proposal to classify these patients as unique entity. Blood. 2012;119(20):4719-4722.

Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol. 2012;156(1):67-75.

Bellos F, Alpermann T, Gouberman E, Haferlach C, Schnittger S, Haferlach T, Kern W. Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen (MNDA) expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. Cytometry B Clin Cytom. 2012;82(5):295-304.

Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, Lippert E, Cermak J, Evans J, Mounier M, Raya JM, Bailly F, Gattermann N, Haferlach T, Garand R, Allou K, Besses C, Germing U, Haferlach C, Travaglino E, Luno E, Pinan MA, Arenillas L, Rozman M, Perez Sirvent ML, Favre B, Guy J, Alonso E, Ahwij N, Jerez A, Hermouet S, Maynadie' M, Cazzola M, Girodon F. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036-1041.

Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, Haferlach C, Hildebrandt B, Iqbal AM, Jhanwar SC, Ohyashiki K, Sole F, Vandenberghe P, Vandyke DL, Zhang Y, Dewald GW. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res. 2012;36(7):832-40.

Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U. Evaluation of BM cytomorphology after allo-SCT in patients with AML. Bone Marrow Transplant. 2012;47(12):1538-1544.

1 / 5